Document Detail


A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice.
MedLine Citation:
PMID:  22642867     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The CHOICE study was a prospective, multicentre, observational study designed to assess the level of adherence in current clinical practice to the European product label and the EORTC guidelines for the treatment of chemotherapy-induced anaemia with darbepoetin alfa (DA).
METHODS: Hb levels and red blood cell (RBC) transfusion requirements were evaluated among 1900 patients with solid tumours in 11 European countries. The primary outcome measure was the proportion of patients with a target Hb level of ≥10-≤12 g/dL after 9 weeks' DA treatment.
RESULTS: The full analysis set (FAS) comprised 1887 patients (mean ± SD age 62.4 ± 11.4 years) divided into categories by baseline Hb < 9 g/dL (n = 281); 9-<10 g/dL (n = 770); 10-<11 g/dL (n = 695); ≥11 g/dL (n = 114). The proportion of patients who remained on the study at week 9 achieving the target Hb level was 37% (n = 60), 48% (n = 217), 54% (n = 210) and 38% (n = 23) in the subgroups with a baseline Hb level of <9 g/dL, 9-<10 g/dL, 10-<11 g/dL and ≥11 g/dL, respectively. In the <9 g/dL, 9-<10 g/dL, 10-<11 g/dL and ≥11 g/dL subgroups of the FAS, the number of patients maintaining Hb levels ≥10 g/dL after their first achievement of an Hb value of 10 g/dL was 95 (34%), 372 (48%), 476 (68%) and 87 (76%), respectively. The Kaplan-Meier percentages of patients who required an RBC transfusion from week 5 until end of treatment period were: 29%, 20%, 12% and 17% in the <9 g/dL, 9-<10 g/dL, 10-<11 g/dL and ≥11 g/dL subgroups, respectively. Kaplan-Meier percentages of patients reaching an Hb level of >13 g/dL were 10%, 9%, 21% and 29%, respectively. Potential bias could not be excluded due to the study's observational nature.
CONCLUSIONS: DA initiation and target Hb ranges adhered to current guidelines in the majority of patients. Furthermore, this study demonstrates faster achievement of the target range and reduced transfusion requirements are associated with initiation of DA at Hb levels of 9-<10 g/dL and 10-<11 g/dL rather than <9 g/dL.
Authors:
S Van Belle; A Swieboda-Sadlej; C Karanikiotis; J-L Labourey; A Galid; T Wheeler; B Pujol; J G Aerts
Related Documents :
9409587 - Clinical observation of the temporal association between crack cocaine and duodenal ulc...
6372937 - Insulin- and histamine-stimulated secretion in relation to recurrence of duodenal ulcer...
19405007 - Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer dev...
24397097 - The role of atrial fibrillation on mortality and morbidity in patients with ischaemic s...
16960447 - Validation of the addenbrooke's cognitive examination for detecting early alzheimer's d...
18705637 - Transradial intervention of iliac and superficial femoral artery disease is feasible.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2012-06-21
Journal Detail:
Title:  Current medical research and opinion     Volume:  28     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-07-09     Completed Date:  2013-01-16     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  1079-87     Citation Subset:  IM    
Affiliation:
Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium. simon.vanbelle@ugent.be
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia / chemically induced*,  drug therapy*
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Blood Transfusion
Breast Neoplasms / blood,  drug therapy
Colorectal Neoplasms / blood,  drug therapy
Erythropoietin / analogs & derivatives*,  therapeutic use
Europe
Female
Guideline Adherence
Hematinics / therapeutic use*
Hemoglobins / analysis
Humans
Lung Neoplasms / blood,  drug therapy
Male
Middle Aged
Neoplasms / blood,  drug therapy*
Ovarian Neoplasms / blood,  drug therapy
Practice Guidelines as Topic
Prospective Studies
Chemical
Reg. No./Substance:
0/Hematinics; 0/Hemoglobins; 11096-26-7/Erythropoietin; 15UQ94PT4P/darbepoetin alfa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced ana...
Next Document:  Molecular characterization of tripartite motif protein 25 (TRIM25) involved in ER?-mediated transcri...